These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 12913055)
1. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Miller AP; Chen YF; Xing D; Feng W; Oparil S Hypertension; 2003 Oct; 42(4):657-63. PubMed ID: 12913055 [TBL] [Abstract][Full Text] [Related]
2. Effect of hormone replacement therapy on inflammatory biomarkers. Georgiadou P; Sbarouni E Adv Clin Chem; 2009; 47():59-93. PubMed ID: 19634777 [TBL] [Abstract][Full Text] [Related]
3. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Stephenson K; Neuenschwander PF; Kurdowska AK Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249 [TBL] [Abstract][Full Text] [Related]
4. Arthur C. Corcoran Memorial Lecture. Hormones and vasoprotection. Oparil S Hypertension; 1999 Jan; 33(1 Pt 2):170-6. PubMed ID: 9931100 [TBL] [Abstract][Full Text] [Related]
5. Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency. Gómez JM; Sahún M; Vila R; Domènech P; Catalina P; Soler J; Badimón L Clin Endocrinol (Oxf); 2006 Jun; 64(6):632-9. PubMed ID: 16712664 [TBL] [Abstract][Full Text] [Related]
6. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Sumino H; Ichikawa S; Ohyama Y; Takahashi T; Saito Y; Nakamura T; Kanda T; Kurabayashi M Am J Cardiol; 2005 Jul; 96(1):148-53. PubMed ID: 15979455 [TBL] [Abstract][Full Text] [Related]
8. An endothelial cell adhesion protein for monocytes recognized by monoclonal antibody IG9. Expression in vivo in inflamed human vessels and atherosclerotic human and Watanabe rabbit vessels. Calderon TM; Factor SM; Hatcher VB; Berliner JA; Berman JW Lab Invest; 1994 Jun; 70(6):836-49. PubMed ID: 8015288 [TBL] [Abstract][Full Text] [Related]
9. Effects of oral and transdermal estrogen therapies on circulating cytokines and chemokines in postmenopausal women with hysterectomy. Yasui T; Saijo A; Uemura H; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M Eur J Endocrinol; 2009 Aug; 161(2):267-73. PubMed ID: 19451213 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Vitale C; Cornoldi A; Gebara O; Silvestri A; Wajngarten M; Cerquetani E; Fini M; Ramires JA; Rosano GM Menopause; 2005; 12(5):552-8. PubMed ID: 16145309 [TBL] [Abstract][Full Text] [Related]
11. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Wakatsuki A; Ikenoue N; Shinohara K; Watanabe K; Fukaya T Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):571-6. PubMed ID: 14699021 [TBL] [Abstract][Full Text] [Related]
13. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Koenig W Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367 [TBL] [Abstract][Full Text] [Related]
14. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Ferrario CM; Strawn WB Am J Cardiol; 2006 Jul; 98(1):121-8. PubMed ID: 16784934 [TBL] [Abstract][Full Text] [Related]
15. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073 [TBL] [Abstract][Full Text] [Related]
16. Adipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy. Tankó LB; Christiansen C Climacteric; 2006 Jun; 9(3):169-80. PubMed ID: 16766431 [TBL] [Abstract][Full Text] [Related]
17. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-7 is associated with monocyte chemoattractant protein-1 and soluble E-selectin levels in peripheral blood of newly post-menopausal women. Yasui T; Saijo A; Uemura H; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M J Reprod Immunol; 2009 Jul; 81(1):97-102. PubMed ID: 19501916 [TBL] [Abstract][Full Text] [Related]
19. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. Davison S; Davis SR J Clin Endocrinol Metab; 2003 Jun; 88(6):2470-8. PubMed ID: 12788842 [TBL] [Abstract][Full Text] [Related]